Northern 2 VCT PLC
Northern 2 VCT PLC is a Venture Capital Trust established under the legislation introduced in the Finance Act 1995. The company’s principal objectives are to invest in a portfolio of quoted and unquoted shares and securities which will, through a combination of income yield and capital growth, provide high long-term returns to shareholders.
Northern 2 VCT was formed in 1999.
The company’s share price is carried daily in the Financial Times (under “Investment Companies - VCTs”), the Daily Telegraph, the Newcastle Journal and the Herald. To obtain an updated share price please click here. Share price information is provided by the London Stock Exchange plc whose terms and conditions you will be required to accept in order to view the information.
The financial calendar for the year ending 31 January 2010 is as follows:
September 2009 half-yearly report for the six months to 31 July 2009 published
December 2009 interim dividend paid
March 2010 Final dividend and results for the year to 31 January 2010 announced; annual report and accounts published
May 2010 Annual general meeting
June 2010 Final dividend paid
Northern 2 VCT PLC is a member of the Association of Investment Companies.
If you would like to receive a copy of the latest published annual report and accounts or half-yearly financial report, by post, please contact us. If you would like to download reports in PDF format, please click here.
Directors
- David Gravells (Chairman)
- Alastair Conn
- Michael Denny
- Christopher Fletcher
- Professor Sir Frederick Holliday
- Frank Neale
Registrars:
- Equiniti Limited (for further information please click here)
Auditors:
- KPMG Audit Plc
Latest news
VCT for income: Northern 3 VCT 15 million share issue offer
Northern 3 VCT PLC has launched a public offer of 15 million new ordinary shares. For further information & the prospectus click here.
Abermed sold to
International SOS
NVM has sold its investment in Abermed, the UK occupational health and remote medical services company, to International SOS, the world's leading provider of integrated medical and security assistance, for an undisclosed consideration. For further information click here.
DxS sold to Qiagen –
record exit for NVM
NVM has sold DxS to Qiagen to create a global leader in personalised medicine for a value of $130 million ($95 million initial consideration plus earnouts of up to $35 million). For further information click here.